Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Driessen

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
FEBS Letters|January 1, 1999
Hyperthermophilic redox chemistry: a re-evaluationP L Hagedoorn, M C Driessen, M van den Bosch, et al.
Oncotarget|September 3, 2016
MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutationsMark Kerstjens, Emma M C Driessen, Merel Willekes, et al.
Haematologica|February 14, 2013
Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infantsEmma M C Driessen, Eddy H J van Roon, Jill A P Spijkers-Hagelstein, et al.
Plos One|March 21, 2015
Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemiaMarieke H van der Linden, Lidija Seslija, Pauline Schneider, et al.
Leukemia|December 7, 2017
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocolE M C Driessen, P de Lorenzo, M Campbell, et al.
British Journal of Haematology|October 3, 2012
CBL mutations do not frequently occur in paediatric acute myeloid leukaemiaEva A Coenen, Emma M C Driessen, C Michel Zwaan, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
FEBS Letters|January 1, 1999
Hyperthermophilic redox chemistry: a re-evaluationP L Hagedoorn, M C Driessen, M van den Bosch, et al.
Oncotarget|September 3, 2016
MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutationsMark Kerstjens, Emma M C Driessen, Merel Willekes, et al.
Haematologica|February 14, 2013
Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infantsEmma M C Driessen, Eddy H J van Roon, Jill A P Spijkers-Hagelstein, et al.
Plos One|March 21, 2015
Identification of genes transcriptionally responsive to the loss of MLL fusions in MLL-rearranged acute lymphoblastic leukemiaMarieke H van der Linden, Lidija Seslija, Pauline Schneider, et al.
Leukemia|December 7, 2017
Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocolE M C Driessen, P de Lorenzo, M Campbell, et al.
British Journal of Haematology|October 3, 2012
CBL mutations do not frequently occur in paediatric acute myeloid leukaemiaEva A Coenen, Emma M C Driessen, C Michel Zwaan, et al.
Pageof 1